With sadness, we mourn the memory of Professor Zhou Jianfeng, a hematology expert who has made outstanding contributions to the hematology community in the mainland.
Written by | Cloth sad frog
Source | "Medical Community Blood Channel" public number
On March 27, 2022, Professor Zhou Jianfeng of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology passed away in Wuhan due to ineffective medical treatment!
The sudden bad news shocked the entire blood science community.
"Said good morning, the result of waiting has become an eternal expectation, may Iron Man rest in peace"
"My good brother, he has helped too many people, whether it is the same people in the industry or difficult and critical patients! He's too tired and too tired! ”
"His departure is a great loss to the entire Chinese hematology community!"
"It was too sudden, yesterday morning I was still lecturing together at the Suzhou Conference, and the other day I was discussing Tianjin cuisine on WeChat, at this moment my mind is blank, I can't believe the bad news from Wuhan! Heaven forbid! ”
"Sad, the scene of communicating with him is vividly remembered"
"I have been in a trance since noon yesterday, I still can't believe the news, I always think I'm having a nightmare"
The blood experts invariably changed their avatars to gray, and the circle of friends was lit by candles all over the screen...
Image source: Ruijing Creative
Call him Professor Zhou, or call him "Iron Man."
In 1997, Professor Zhou Jianfeng successfully completed his doctoral studies, and after graduation, he stayed at his alma mater to continue his medical career and scientific research.
In 2001, Professor Zhou Jianfeng returned from further study in the United States, and two years later, he was entrusted with the responsibility of director of the Department of Hematology of Tongji Hospital. The self-proclaimed "Rookie Director", he rotated almost all departments of internal medicine: "Learning comes from practice, and as a doctor you must experience in the clinic." ”
20 years ago, the development of China's blood field was relatively backward, and hematology was both niche and difficult for most clinicians to understand. In particular, the diagnosis and treatment of lymphoma has a very large particularity in China, and there is no relevant diagnostic technology in China, and foreign treatment methods cannot be used.
Professor Zhou Jianfeng said, "Lymphoma is both between hematology and oncology, and different departments will contact such patients, but at that time, there was a lack of very good diagnosis and treatment norms in China, and patients not only often took the wrong road, but many people spent money and could not achieve the treatment effect he should achieve." ”
He hopes to lead the team to make a difference in the field of hematological tumors.
Ten years of grinding a sword, Professor Zhou Jianfeng led the hematology team of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology to publish more than 100 papers in international journals, with a total impact factor of more than 400 points, and more than 2,000 SCI citations in 5 years.
In 2015, Professor Zhou Jianfeng's team successfully implemented the first CAR-T therapy in central China to treat recurrent acute lymphoblastic leukemia, the world's first two kinds of CAR-T cell sequential refusion therapy, and applied CAR-T therapy to lymphoma, multiple myeloma and other fields.
At the ASH2020 conference, Professor Zhou Jianfeng's team announced a research result of CD19/CD22CAR-T cell cocktail therapy after autologous transplantation in the treatment of relapsed refractory B cell lymphoma with a total efficiency of up to 90.5%!
Since then, Zhou Jianfeng's team has continued to innovate and develop, using the CAR-T therapy of fully human BCMA (CT103A) for the clinical treatment of multiple myeloma, achieving excellent safety and efficacy, and has a long-lasting body duration. In February 2021, the technology was recognized as a "breakthrough therapeutic drug" by the State Drug Administration.
At the same time, since the treatment of blood tumors related to EBV infection in mainland China has not been mature solutions, Professor Zhou Jianfeng took the lead in leading the team to carry out research and exploration in EBV-related lymphoma. He called it the "Jiaolong Project", jiaolong is the deepest diving deep-sea probe independently developed by the Chinese, which has reached the world's advanced level, and he hopes to carry out more original and breakthrough research under this name to benefit patients.
Zhou Jianfeng's project "Innovative CAR-T Research on the Treatment of Refractory EBV-Related Lymphoproliferative Diseases with EBV as a Target" won the key project of the National Natural Science Foundation of China. Through the unremitting efforts of the team and the exploration of the pathogenesis of the disease, Professor Zhou Jianfeng has become a well-known expert in the field of hematological tumors caused by hemophagocytic syndrome and EPV infection in China.
Light, and the light chaser
As of today, CSCO, the Chinese Medical Association Hematology Branch, the Chinese Anti-Cancer Association and other public accounts have successively issued articles to mourn Professor Zhou Jianfeng.
Figure Professor Zhou Jianfeng
Professor Zhou Jianfeng is a leader in the development of CAR-T in China.
"For patients with hematological tumors who are difficult to treat and whose existing technology is exhausted, CAR-T is their life-saving herd, and a considerable number of lymphoma patients can achieve a curative effect, and even in the field of lymphoma, CAR-T treatment can be the ultimate treatment," Professor Zhou Jianfeng stressed in an interview. All along, Professor Zhou Jianfeng and his team have been carrying out arduous technical research to try to eliminate the "last mile" of tumors.
From this academic self-confidence and determination for the future, Professor Zhou Jianfeng brings courage and hope to patients who are on the verge of life and death.
In 2017, a patient in the United States with two tumors, acute lymphoblastic leukemia and gastrointestinal stromal tumor, recurred after multiple chemotherapy and bone marrow transplants. Unable to queue up, unable to wait for commercial CAR-T, desperate to find Professor Zhou Jianfeng's team. After a year and a half of treatment, she once lamented: "My second life began in Tongji. ”
Since 2016, Professor Zhou Jianfeng has led the team to apply CAR-T treatment, which has benefited more than 600 patients from the United States, Australia, Southeast Asia, Dubai, Hong Kong, Beijing, Shanghai and other countries and regions.
Figure Hong Kong's first LEUK patient undergoing CAR-T treatment took a group photo after the disease remission (Source: Central China University Tongji Graduate Student Public Account)
Figure Group photo of disease relief after CAR-T treatment for patients with leukemia in Dubai (Source: Central China Tongji Graduate Student Public Account)
"The man who brought us the light is gone"
Yesterday, Gu Hongfei, the founder of "Lymphoma Home", posted a memorial on the platform: "The person who brought us light is gone."
Figure from the House of Lymphoma
One patient left a message below, recalling his relationship with the professor: "I will always remember him easily saying that Hodgkin was a small ailment, and that after a few years of being cured, he could have children and live like a normal person." Every time I see his new achievements and new breakthroughs on the forum, I have more peace of mind and confidence in my future.
He practiced what he preached, igniting hope and light again and again in times of despair.
Professor Zhou Jianfeng said, "No matter how busy and tired you are, when you see a patient you treat, a patient who was once desperate, after full treatment and return to life, you will feel that all your efforts are worth it." For a doctor, I think this is the most touching moment. ”
In addition to grief and regret, the family of a lymphoma patient also indignantly appealed: Because of this, we should strive to go in the direction of the light and give the most powerful attention to the doctor who brought the light to everyone.
Figure from Weibo
Do you believe in the Light?
As long as the Light Chaser is still there!
The light that follows will be there!
We've been there all along!
The world
Iron Man has come
Iron Man is gone
Let him rest for a while
He was going to another world to continue saving lives
All the way up...
bibliography:
[1] Sina Weibo.
[2] "The Life Mentor Who Created the Dream of Medicine — Zhou Jianfeng" is the public account of Tongji Graduate Students of Central China University.
Source: Medical Community Blood Channel
Editor-in-charge: Zheng Huaju
Proofreader: Zang Hengjia
Plate making: Xue Jiao